JNJ241108C182500
- 0.02
- 0.000.00%
Johnson & Johnson Newsroom
Johnson & Johnson (JNJ.US) monoclonal antibody therapy achieves Phase 3 clinical primary endpoints significantly delaying high-risk SMM progression.
The American Society of Hematology (ASH) released abstracts of some studies at its 2024 conference.
SA Asks: How Will the U.S. Election Results Impact Healthcare Stocks?
Johnson & Johnson Analyst Ratings
Why Most Healthcare Stocks Are Falling With Trump's Win, With Some Exceptions
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields
Guggenheim Maintains Johnson & Johnson(JNJ.US) With Hold Rating, Cuts Target Price to $162
Guggenheim Adjusts Johnson & Johnson's Price Target to $162 From $156, Keeps Neutral Rating
Express News | Global first BCMA x CD3 bispecific drug Tlachol is launched in China.
Johnson & Johnson Darzalex Shows Efficacy in Early-stage Multiple Myeloma
AI Robot Trader Dumped Microsoft, Amazon Stocks and Went Defensive. Here's What It Bought. -- Barrons.com
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
With 73% Ownership of the Shares, Johnson & Johnson (NYSE:JNJ) Is Heavily Dominated by Institutional Owners
Express News | Pharma Mar - Reaches Commercial Milestone About Yondelis (Trabectedin) in United States
Is Johnson & Johnson (JNJ) the Best Pharma Stock to Buy Right Now?
Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
Alvotech, Advanz's Application for AVT05 Accepted by European Medicines Agency
New Study Reveals Another Benefit in Using Novo Nordisk's Wegovy in Obesity
Express News | The results of the national medical insurance negotiations are expected to be released at the end of November 2024.
Stocks That Hedge Funds Moved From Long to Short in August - Jefferies
Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific